Business Context and Reporting Period
Company: Recursion Pharmaceuticals, Inc. (RXRX)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2024
Business Overview: Recursion is a clinical-stage TechBio company utilizing its Recursion Operating System (OS) to decode biology and industrialize drug discovery. The company focuses on precision oncology, rare diseases, and infectious diseases. As of June 30, 2024, the company had an accumulated deficit of approximately $1.2 billion and expects to incur substantial operating losses in future periods.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2024 | Balance Sheet (June 30, 2024) |
|---|---|---|---|
| Total Revenue | $14,417 | $28,211 | - |
| Net Loss | $(97,540) | $(188,913) | - |
| Operating Loss | $(100,543) | $(196,883) | - |
| Research & Development Expense | $73,928 | $141,488 | - |
| Cash and Cash Equivalents | - | - | $474,341 |
| Restricted Cash | - | - | $8,412 |
| Total Debt (Notes & Leases) | - | - | $31,030 |
| Stockholders' Equity | - | - | $584,449 |
Note: Revenue is primarily derived from strategic collaboration agreements (e.g., Roche/Genentech) and grants. The company has no approved products for commercial sale.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 31% year-over-year for the quarter and 22% for the six-month period, driven by revenue recognition from the Roche collaboration as work shifted toward higher-cost processes.
- Expense Increases:
- R&D Expenses: Increased 34% (quarter) and 39% (six months) due to platform expansion, internal pipeline activities, and personnel costs.
- General & Administrative: Increased 13% (quarter) and 24% (six months), primarily due to higher salaries, software, and lease expenses.
- Net Loss Expansion: Net loss increased 27% for the quarter and 33% for the six-month period compared to the prior year, reflecting the acceleration of R&D and platform investments.
- Financing Activity: In June 2024, the company completed a public offering of 35.4 million shares, raising net proceeds of approximately $216.4 million. Additionally, $56.0 million was raised via At-The-Market (ATM) offerings in the first half of 2024.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Liquidity: Management believes existing cash and cash equivalents ($474.3 million) are sufficient to fund operations for at least the next 12 months.
- Exscientia Acquisition: On August 8, 2024, Recursion signed an agreement to acquire Exscientia plc in an all-stock transaction. The combined entity is expected to have a cash runway extending into 2027 and estimated annual synergies of $100 million or more.
- Pipeline Milestones:
- Roche Collaboration: Roche accepted the first neuroscience Phenomap in August 2024, triggering a $30.0 million milestone payment (recognized as variable consideration).
- Clinical Trials: Phase 2 data for CCM (REC-994) expected in September 2024; preliminary safety/efficacy for NF2 (REC-2282) expected in Q4 2024.
Risks and Contingencies
- Internal Controls: The company disclosed that its disclosure controls and procedures were ineffective as of June 30, 2024, due to a material weakness in internal control over financial reporting related to revenue recognition cost models. Remediation is in progress but not yet complete.
- AI Regulation: New regulations, such as the EU AI Act, may impose significant compliance costs and operational constraints on the company's AI-driven drug discovery platform.
- Capital Requirements: The company expects to require additional capital to advance drug candidates and commercialize products. Failure to raise capital could force delays or abandonment of programs.
- Legal Proceedings: Ongoing litigation with a landlord (Industry Office SLC, LLC) regarding a lease dispute; no liability recorded as an unfavorable outcome is not currently probable.
Investor Verification Checklist
- Remediation of Material Weakness: Verify the timeline and testing results for the remediation of the internal control weakness regarding revenue recognition.
- Exscientia Transaction Status: Monitor shareholder votes and regulatory approvals required to close the Exscientia acquisition.
- Cash Burn Rate: Assess the sustainability of the current cash runway given the increased R&D spend and the timeline for potential product revenue.
- Roche Milestone Recognition: Confirm the accounting treatment and timing of the $30 million Roche milestone payment recognized in Q3 2024.
- Stock-Based Compensation: Review the impact of increasing stock-based compensation (up 91% in R&D for the quarter) on future dilution and expense.